Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes
Ana M. Blázquez-Medela
Renal and Cardiovascular Pathophysiology Unit, Institute Queen Sofía of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Search for more papers by this authorLuis García-Ortiz
Research Unit, Primary Care Centre La Alamedilla, SACYL, Salamanca, Spain
Search for more papers by this authorManuel A. Gómez-Marcos
Research Unit, Primary Care Centre La Alamedilla, SACYL, Salamanca, Spain
Search for more papers by this authorJosé I. Recio-Rodriguez
Research Unit, Primary Care Centre La Alamedilla, SACYL, Salamanca, Spain
Search for more papers by this authorAngel Sánchez-Rodríguez
Internal Medicine Service, University Hospital of Salamanca, Salamanca, Spain
Search for more papers by this authorJosé M. López-Novoa
Renal and Cardiovascular Pathophysiology Unit, Institute Queen Sofía of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Search for more papers by this authorCarlos Martínez-Salgado
Renal and Cardiovascular Pathophysiology Unit, Institute Queen Sofía of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Institute of Studies in Health Sciences of Castilla y León (IECSCYL), Research Unit, University Hospital of Salamanca, Salamanca, Spain
Search for more papers by this authorAna M. Blázquez-Medela
Renal and Cardiovascular Pathophysiology Unit, Institute Queen Sofía of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Search for more papers by this authorLuis García-Ortiz
Research Unit, Primary Care Centre La Alamedilla, SACYL, Salamanca, Spain
Search for more papers by this authorManuel A. Gómez-Marcos
Research Unit, Primary Care Centre La Alamedilla, SACYL, Salamanca, Spain
Search for more papers by this authorJosé I. Recio-Rodriguez
Research Unit, Primary Care Centre La Alamedilla, SACYL, Salamanca, Spain
Search for more papers by this authorAngel Sánchez-Rodríguez
Internal Medicine Service, University Hospital of Salamanca, Salamanca, Spain
Search for more papers by this authorJosé M. López-Novoa
Renal and Cardiovascular Pathophysiology Unit, Institute Queen Sofía of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Search for more papers by this authorCarlos Martínez-Salgado
Renal and Cardiovascular Pathophysiology Unit, Institute Queen Sofía of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain
Institute of Studies in Health Sciences of Castilla y León (IECSCYL), Research Unit, University Hospital of Salamanca, Salamanca, Spain
Search for more papers by this authorAbstract
Eur J Clin Invest 2012; 42 (5): 548–556
Background Osteoprotegerin (OPG), a secreted member of the tumour necrosis factor receptor superfamily of cytokines, has been associated with endothelial dysfunction. We studied in type 2 diabetic and/or hypertensive patients the relationship between serum OPG and vascular alterations associated with these pathologies.
Materials and methods We analysed 191 consecutive patients (52 with type 2 diabetes and 139 hypertensive nondiabetic patients) and 54 healthy controls. We assessed the relationship of OPG serum levels measured by ELISA with basal glycaemia, glycosylated haemoglobin, blood pressure, endothelial dysfunction (assessed by pulse wave velocity), retinopathy (by Keith-Wagener classification), left ventricular hypertrophy (by Cornell index), cardiovascular risk and target organs (heart, vascular, kidney) damage.
Results Serum OPG levels were higher in either hypertensive or diabetic patients and in patients with non-dipper and riser circadian blood pressure patterns. We found significant correlations between OPG levels and age, height, glycaemia, systolic, diastolic and pulse blood pressure, pulse wave velocity and left ventricular hypertrophy in both hypertensive and diabetic patients. OPG levels were also higher in hypertensive patients with retinopathy, patients with high probability of 10-year cardiovascular risk, patients with three or more damaged target organs (heart, vessels, kidneys) and patients with previous episodes of ischaemic cardiopathy or hypercholesterolaemia.
Conclusions Osteoprotegerin is an indicator of diabetes- and hypertension-associated vascular pathologies as endothelial dysfunction and cardiovascular risk.
References
- 1 Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540–5.
- 2 Potenza MA, Gagliardi S, Nacci C, Carratu’ MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009; 16: 94–112.
- 3 Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105: 32S–9S.
- 4 Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32(Suppl 2): S314–21.
- 5 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19.
- 6 Schoppet M, Preissner KT, Hofbauer LC. RANK Ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549–53.
- 7 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631–7.
- 8 Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154: 75–81.
- 9 Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39–42.
- 10 Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes 2009; 117: 119–23.
- 11 Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine 2008; 44: 168–71.
- 12 Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664–6.
- 13 von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.
- 14 Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40: 35–53.
- 15 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
- 16 Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–7.
- 17 Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, Recio-Rodríguez JI, Sánchez-Rodríguez A, López-Novoa JM et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010; 8: 86.
- 18 Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156–61.
- 19 Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25: 417–23.
- 20 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–12.
- 21 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70.
- 22 Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974; 268: 336–45.
- 23 Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
- 24 Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006; 64: 652–8.
- 25 Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010; 59: 742–7.
- 26 Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006; 169: 2236–44.
- 27 Schrader J, Rennekamp W, Niebergall U, Schoppet M, Jahr H, Brendel MD et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007; 50: 1243–7.
- 28 Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K et al. Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women. Menopause 2008; 15: 180–4.
- 29 Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111: 3119–25.
- 30 Huvers FC, De Leeuw PW, Houben AJ, De Haan CH, Hamulyak K, Schouten H et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 48: 1300–7.
- 31 Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434–9.
- 32 van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001; 32: 454–60.
- 33 Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10–5.
- 34 Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085–90.
- 35 McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006; 48: 602–8.
- 36 Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens 2010; 23: 586–91.
- 37 Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850–7.
- 38 Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007; 9: 357–63.
- 39 Noheria A, Mosley TH Jr, Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens 2010; 23: 767–74.
- 40 Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100–7.
- 41 Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67: 1576–82.
- 42 Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55: 2049–61.
